Hohl Benjamin 4

What Happened
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics (ELVN), received equity awards reported on Feb 12, 2026. The filing shows two grants: 25,000 shares (awarded at $0.00) and 150,000 derivative shares (awarded at $0.00), for a total of 175,000 restricted stock units (RSUs). These are compensatory grants (not open‑market purchases or sales) and do not represent immediate stock ownership until the RSUs vest.

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (appears timely given the federal holiday on Feb 16).
• Grants: 25,000 RSUs (direct award) and 150,000 derivative RSUs (reported as derivative award). Price: $0.00 per unit (standard for RSU compensation).
• Shares owned after transaction: Not specified in the portion of the filing provided.
• Vesting (per footnotes): 1/4 of the RSUs will vest on March 1, 2027, then 1/16th will vest each June 1, Sept 1, Dec 1 and March 1 thereafter, subject to continued service. (Footnote F2 confirms certain securities are RSUs; F3 in the filing references a separate option vesting schedule.)
• Filing timeliness: Filing date is within the required two business days given the Feb 16 holiday, so this appears timely.

Context
RSUs are a form of compensation that convert into shares only after vesting; they do not represent immediate cash proceeds or open‑market buying/selling. Grants like these are common for executive pay and reflect future incentive compensation rather than an immediate insider purchase or sale.